Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications

Area of Science:

• Oncology
• Breast Cancer Research
• Molecular Subtyping

Background:

• HER2-positive breast cancer was historically treated as a single subtype, using a uniform approach for early breast cancer (eBC).
• Current anti-HER2 therapies in eBC often use a chemotherapy backbone, irrespective of tumor endocrine sensitivity, based on metastatic setting data.
• Emerging data reveal differential response rates to neoadjuvant chemotherapy plus HER2-targeted therapy based on hormone receptor (HR) status.

Purpose of the Study:

• To highlight the need for personalized anti-HER2 therapy in early breast cancer (eBC).
• To explore the impact of molecular subtypes and endocrine responsiveness on treatment outcomes.
• To discuss strategies for optimizing treatment and minimizing resistance in HER2-positive eBC.

Main Methods:

• Analysis of recent clinical trial data comparing treatment responses in HR-negative versus HR-positive HER2-positive tumors.
• Review of preclinical and emerging clinical evidence on the crosstalk between endocrine and HER2 pathways.
• Consideration of molecular subtyping and early response monitoring techniques (e.g., re-biopsy, dynamic biomarkers, molecular imaging).

Main Results:

• Pathological complete response (pCR) has a varying impact on patient outcomes, particularly significant in HR-negative disease.
• Preclinical and early clinical data suggest meaningful pathological responses with co-targeting of Estrogen Receptor (ER) and HER2 pathways.
• HER2-positive tumors show differential responses to neoadjuvant therapy based on HR status.

Conclusions:

• Individualizing anti-HER2 therapy in eBC based on endocrine responsiveness and relapse risk is crucial.
• Co-targeted approaches against ER and HER2 pathways show promise.
• Molecular subtyping and early response monitoring are key to avoiding overtreatment and resistance in HER2-positive eBC.